Top Markets
#1 Islamic Coin Islamic Coin +154.45%
#2 PulseChain PulseChain +48.38%
#3 Ergo Ergo +30.11%
#4 RedStone RedStone +16.56%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.64%
#6 SkyAI SkyAI +10.52%
#7 Siren Siren +8.99%
#8 Lighter Lighter +8.81%
#9 Monad Monad +8.67%
#10 OPENLOOT OPENLOOT +8.16%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc.

COEP
Rank in Stocks #28029
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates... Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Share Price
$4.81
Last synced: 2026-07-27
Market Cap
$29.01M
Change (1 day)
-8.56%
Change (1 year)
-64.66%
Country
US
Trade Coeptis Therapeutics Holdings, Inc. (COEP)

Category

Healthcare
Revenue for Coeptis Therapeutics Holdings, Inc. (COEP)
Revenue in Aug 2026 TTM: 0
According to Coeptis Therapeutics Holdings, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Coeptis Therapeutics Holdings, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH